Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

AstraZeneca Clinical Study Information Center 1-877-240-9479
information.center@astrazeneca.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Back

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Recruiting

Open to: ALL

Age: 18.0 - 130.0

Cambridge Manchester Oxford London London Taunton

Medical Conditions

Adenocarcinoma
Stomach Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Mar 2024 Apr 2026

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Participants in the AZD0901 arm 1 will receive dose level 1 AZD0901 IV

Intervention Arm Group : AZD0901 arm 1;

Intervention Type : DRUG
Intervention Description : Participants in the AZD0901 arm 2 will receive dose level 2 AZD0901 IV

Intervention Arm Group : AZD0901 Arm 2;

Intervention Type : DRUG
Intervention Description : Ramucirumab 8 mg/kg IV on Days 1 and 15 and paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W

Intervention Arm Group : Investigator's choice arm;

Intervention Type : DRUG
Intervention Description : Paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W (for participants with contraindication to ramucirumab only)

Intervention Arm Group : Investigator's choice arm;

Intervention Type : DRUG
Intervention Description : Docetaxel 75-100 mg/m2 IV on Day 1, Q3W (for participants with contraindication to ramucirumab only)

Intervention Arm Group : Investigator's choice arm;

Intervention Type : DRUG
Intervention Description : Irinotecan 150-180 mg/m2 IV on Days 1 and 15, Q4W

Intervention Arm Group : Investigator's choice arm;

Intervention Type : DRUG
Intervention Description : TAS-102 35 mg/m2 up to a maximum of 80 mg orally twice a day on Days 1 to 5 and Days 8 to 12, Q4W (except China)

Intervention Arm Group : Investigator's choice arm;

Intervention Type : DRUG
Intervention Description : Apatinib 500-850 mg at Investigator's discretion based on participant's condition and tolerability, orally once daily, Q4W (China only)

Intervention Arm Group : Investigator's choice arm;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Research Site
    Cambridge
    CB2 0QQ
  • Research Site
    Manchester
    M20 4BX
  • Research Site
    Oxford
    OX3 7LE
  • Research Site
    London
    SW3 6JJ
  • Research Site
    London
    EC1A 7BE
  • Research Site
    Taunton
    TA1 5DA

AstraZeneca Clinical Study Information Center 1-877-240-9479
information.center@astrazeneca.com



The study is sponsored by AstraZeneca



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT06346392
Last updated 08 May 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top